Comparative Pharmacology
Head-to-head clinical analysis: CLADRIBINE versus FOLOTYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLADRIBINE versus FOLOTYN.
CLADRIBINE vs FOLOTYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
FOLOTYN (pralatrexate) is a folate analogue metabolic inhibitor that competes for the reduced folate carrier and folylpolyglutamate synthetase, leading to intracellular accumulation of polyglutamated metabolites that inhibit dihydrofolate reductase (DHFR) and thymidylate synthase, thereby disrupting DNA synthesis and cell proliferation.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
3.0 mg/m2 intravenously over 3-5 minutes on days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Clinical Note
moderateCladribine + Digoxin
"Cladribine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCladribine + Digitoxin
"Cladribine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCladribine + Deslanoside
"Cladribine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCladribine + Acetyldigitoxin
"Cladribine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Terminal elimination half-life is approximately 4–6 hours; clinical context: supports weekly dosing schedule.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Primarily renal excretion (approximately 80% of the dose recovered in urine over 24 hours, with about 60% as unchanged drug); biliary/fecal elimination accounts for <1%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent